Related Experiment Videos
Carbamazepine dose-frequency requirement in children
Insights
Optimizing carbamazepine (CBZ) dosing in children requires understanding daily drug level fluctuations. More frequent dosing reduces concentration variability, improving therapeutic outcomes and minimizing toxicity risks.
Area of Science:
- Pediatric Pharmacology
- Clinical Pharmacy
- Pharmacokinetics
Background:
- Carbamazepine (CBZ) is a widely used antiepileptic drug in children.
- Understanding optimal dosing regimens is crucial for efficacy and safety.
- Daily fluctuations in drug levels can impact treatment outcomes.
Purpose of the Study:
- To investigate the dose-frequency requirements for carbamazepine in pediatric patients.
- To determine the impact of different dosing frequencies on daily fluctuations in CBZ saliva concentrations.
- To correlate drug levels with toxic features and therapeutic range adherence.
Main Methods:
- Serial saliva samples were collected from 6 children (6-13 years) in a steady state.
- Carbamazepine concentrations were measured under two different dose-frequency regimens.
- Pharmacokinetic parameters, including half-life and volume of distribution, were analyzed.
Main Results:
- More frequent dosing resulted in smaller fluctuations in saliva carbamazepine concentrations.
- A shorter time with drug levels outside the therapeutic range was observed with optimized frequency.
- Toxic features and convulsions correlated with peak and trough concentrations, not total dose.
- Saliva CBZ half-lives ranged from 7.3 to 12.7 hours.
Conclusions:
- Saliva carbamazepine concentrations provide a convenient method for individualizing pediatric dosage.
- Optimizing dosing frequency is key to minimizing fluctuations and improving therapeutic drug monitoring.
- Pharmacokinetic data from saliva samples support rational prescribing of carbamazepine in children.
Abstract:
The dose-frequency requirement for carbamazepine (CBZ) in children was investigated using serial saliva samples to determine the daily fluctuation in drug levels. Mixed saliva was collected from 6 children (aged between 6 and 13 years) in a steady state, on each of two different dose-frequency resulted in smaller fluctuations in saliva concentration and a shorter time with levels outside the therapeutic range. Toxic features and convulsions appeared to be related to peak and trough concentrations. There was no apparent relationship between the total dose and the mean saliva concentration. The saliva CBZ half-lives in 2 children were 7.3 and 12.7 hours, and the apparent volumes of distribution (saliva) were 1.6 and 1.5 l/kg respectively. Saliva CBZ concentrations are an efficient and convenient means of tailoring individual dosage, and can be used to provide the pharmacokinetic data that rational prescribing demands.